Speakers

Presenter: Taylor Jansen, PhD
Labcorp
VP, Oncology R&D Science
Burlington, North Carolina

Event Description

The landscape of drug development has evolved significantly in recent years, propelled by advancements in biomarker detection and targeted therapies. Liquid biopsy represents a transformation in the management of oncology patients given its potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional modalities. Additional value lies in its non-invasive nature, availability and accessibility, which enables other sampling options when tissue is not available or insufficient.​

In this symposium, we demonstrate the promising role of Molecular Residual Disease (MRD) detection using a tumor-informed ctDNA assay that uses integrated whole genome sequencing (WGS) and proprietary machine learning to provide sensitive, specific and time-efficient MRD detection for clinical trials and therapeutic development programs. ​

We will show how combining the power of molecular and immune profiling to drive molecular-based testing is improving stratification methods and patient outcomes. We will also showcase the impact of a scalable comprehensive assay and infrastructure in the context of drug development.​